The first oral GLP-1 pill received FDA approval on December 22, 2025 with introductory pricing of $149 per month for the lowest dose
(E(X)-4)(2)-Fc, an effective long-acting GLP-1 receptor agonist, reduces obesity-related inflammation by inhibiting leptin expression
Nielsen J, Friedman S, Norgard BM, Knudsen T, Kjeldsen J, Wod M
These criteria represent common consumer considerations and are not medical recommendations
By Drug Type, Liraglutide Segment Accounts for 35.5% Market Share The liraglutide segment is projected to account for 35.5% of the GLP-1 diabetes treatment drugs market in 2025, reaffirming its position as the leading drug type category
Some users report fewer GI issues when injecting in the evening so they sleep through the worst of any nausea